SCHEMBL20004649

SCHEMBL20004649

Brc1cnc2[nH]c(I)cc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 6/20 0.43
AURKA O14965 3/20 0.43
JAK2 O60674 3/20 0.43
MAP4K4 O95819 3/20 0.43
FGFR1 P11362 3/20 0.43
FLT1 P17948 3/20 0.43
KDR P35968 3/20 0.43
CLK2 P49760 3/20 0.43
CDK5 Q00535 3/20 0.43
MAP4K2 Q12851 3/20 0.43
AURKB Q96GD4 3/20 0.43
CLK4 Q9HAZ1 3/20 0.43
DYRK1B Q9Y463 3/20 0.43
PRKD3 O94806 2/20 0.43
TAOK1 Q7L7X3 2/20 0.43
DAPK3 O43293 2/20 0.43
PAK4 O96013 2/20 0.43
ABL1 P00519 2/20 0.43
RET P07949 2/20 0.43
PDGFRA P16234 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15907680 0.76 KIT (0.46) KDM4EKIT
SCHEMBL15839990 0.76 KIT (0.40) KIT
SCHEMBL20004561 0.76 SNCA (0.42) KIT
SCHEMBL2038921 0.76 BRD4 (0.47) DYRK1AAURKAJAK2MAP4K4FGFR1
SCHEMBL15750978 0.76 DYRK1A (0.43) DYRK1AAURKAJAK2MAP4K4FGFR1
Hydrochloric Acid SCHEMBL15825545 0.74 KIT (0.39) KIT
SCHEMBL25153577 0.72 DYRK1A (0.43) DYRK1AAURKAJAK2MAP4K4FGFR1
SCHEMBL12019625 0.72 GCK (0.41) DYRK1AAURKAJAK2MAP4K4FGFR1
SCHEMBL16537462 0.72 ABL1 (0.51) DYRK1AAURKAJAK2MAP4K4FGFR1
SCHEMBL25153266 0.72 BRD4 (0.50) DYRK1AAURKAJAK2MAP4K4FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10906900-B2 Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2021-02-02 US disclosed
US-10906900-B2 Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2021-02-02 US disclosed
EP-3515912-B1 COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES CENTRE NAT RECH SCIENT (FR) 2020-10-14 EP disclosed
US-20190211011-A1 COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-07-11 US disclosed
US-20190211011-A1 COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-07-11 US disclosed
WO-2018055316-A1 COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10906900-B2 Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases PSEN2, CLN6, MAPT DYRK1A 4671/4885AURKA 3931/4885JAK2 4810/4885
US-20190211011-A1 COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES PSEN2, SNCA, MAPT DYRK1A 4663/4885AURKA 3987/4885JAK2 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.